deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT03132324

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Sponsor: Incyte Corporation

Conditions Sickle Cell Disease
Interventions INCB059872
Updated 14 times since 2017 Last updated: Oct 24, 2019 Started: Apr 20, 2017 Primary completion: Oct 3, 2018 Completion: Oct 3, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Sickle Cell Disease trials with similar outcome

Browse all Sickle Cell Disease trials

This PHASE1 trial investigates Sickle Cell Disease and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Feb 2018 · 8 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Nov 2019 · 7 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 9 earlier versions

  1. Nov 2019 — Nov 2020 [monthly]

    Terminated PHASE1

  2. Apr 2019 — Nov 2019 [monthly]

    Terminated PHASE1

  3. Nov 2018 — Apr 2019 [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  4. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  5. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  6. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  7. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  8. Jun 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. May 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations